The U.S. Food and Drug Administration has approved a subcutaneous version of Sarclisa Escena (isatuximab‑irfc) for adults with multiple myeloma, adding a new injection option to the drug’s existing intravenous formulation.
Patients can now choose a needle option.
New delivery method expands treatment choices
Sarclisa Escena can be administered under the skin using the CirCLIQ On‑Body Delivery System or by a healthcare provider with a syringe. The dose is a 1,400‑milligram injection given as part of a combination regimen. This option may be more convenient for patients who prefer to avoid an IV infusion, though it remains the same antibody therapy that targets the CD38 protein on myeloma cells.
The approval covers three distinct treatment settings. First, it may be combined with Pomalyst (pomalidomide) and dexamethasone for patients whose disease has returned after at least one prior therapy. Second, it is authorized with Kyprolis (carfilzomib) and dexamethasone for those whose cancer has relapsed or become resistant after one to three earlier treatments. Third, Sarclisa Escena can be paired with Velcade (bortezomib), Revlimid (lenalidomide) and dexamethasone for newly diagnosed patients who are not candidates for an autologous stem cell transplant.
Related: Many Users Find Their Accounts Blocked
Clinical trial data underpin the decision
Regulators based the approval on three studies that examined the subcutaneous formulation in different patient groups. The largest trial, IRAKLIA, enrolled more than 500 participants with previously treated disease. In that study, the response rate was about 71 % for the injection, compared with roughly 70 % for the IV version, indicating comparable efficacy.
Another trial, IZALCO, looked at the drug combined with Kyprolis and dexamethasone in relapsed or refractory patients. Nearly 80 % of participants showed a response. The third study, IsaSocut, focused on newly diagnosed individuals ineligible for stem‑cell transplant; when Sarclisa Escena was added to Velcade, Revlimid and dexamethasone, response was observed in 97.3 % of patients.
While response rates give a sense of how well a therapy controls disease, they do not guarantee cure or uniform benefit across all patients. The consistency of drug exposure between the injection and IV forms was also confirmed, supporting the claim that the two delivery methods are interchangeable from a pharmacokinetic standpoint.
From a broader perspective, adding a subcutaneous option reflects a gradual shift in oncology toward more patient‑friendly administration routes. As cancer care moves beyond the hospital setting, therapies that can be given with less time in infusion chairs may improve quality of life and reduce resource strain on clinics.
Related: Can You Have a Food Poisoning Treatment at Home with IV Therapy?
Safety profile and patient considerations
Like other antibody treatments, Sarclisa Escena carries risks. The prescribing information warns of potential allergic or infusion‑related reactions, neutropenia, infections, secondary malignancies, laboratory test interference, and fetal harm. Patients are advised to discuss these risks with their care team and weigh them against the expected benefits in their specific disease context.
Administration is always part of a combination regimen, meaning that clinicians must manage overlapping toxicities from the partner drugs. Monitoring for low white‑blood‑cell counts and infection signs remains a standard part of therapy.
Overall, the FDA’s decision adds a practical alternative for clinicians treating multiple myeloma, aligning with ongoing efforts to tailor treatment delivery to individual patient needs.
